enGene Therapeutics (ENGN) Cash from Financing Activities (2023 - 2026)

enGene Therapeutics (ENGN) has reported Cash from Financing Activities for 4 consecutive years, with $74000.0 the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 62.81% year-over-year to $74000.0; the TTM figure through Apr 2026 stood at $143.1 million (up 136.81% YoY), while the FY2025 annual figure was $1.5 million, down 99.43% from the prior year.
• Cash from Financing Activities slipped to $74000.0 in Q2 2026 per ENGN's latest filing, from $141.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $193.5 million in Q2 2024 and bottomed at -$667000.0 in Q3 2025.
• Historically, Cash from Financing Activities has averaged $35.4 million across 4 years, with a median of $4.9 million in 2023.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 1407.84% — and 2026, when it jumped 14165900.0%.
• enGene Therapeutics' Cash from Financing Activities stood at $50.8 million in 2023, then advanced by 18.33% to $60.2 million in 2024, then plunged by 96.69% to $2.0 million in 2025, then slumped by 96.28% to $74000.0 in 2026.
• Business Quant data shows ENGN's Cash from Financing Activities at $74000.0 in Q2 2026, $141.7 million in Q1 2026, and $2.0 million in Q4 2025.